Hopital Henri Mondor - 1 rue Gustave Eiffel
- Address
- Av du Mal de Lattre de Tassigny, 94000 Créteil, France
Hopital Henri Mondor - Advanced Hematologic Malignancies and Solid Tumor Research Center
Hopital Henri Mondor is a leading research institution specializing in hematologic malignancies and advanced cancer therapeutics. The center demonstrates particular expertise in rare blood disorders and novel targeted therapies, conducting cutting-edge clinical trials across multiple oncologic subspecialties.
- Myeloproliferative neoplasms and chronic myelogenous leukemia, including JAK2V617F-positive disorders and blast crisis management
- Multiple myeloma and lymphomas, with focus on relapsed/refractory disease and primary CNS lymphoma
- Advanced solid tumors including metastatic NSCLC with KRAS G12C mutations
- Rare hematologic conditions including blastic plasmacytoid dendritic cell neoplasms
The center's research portfolio extends beyond oncology to include transthyretin amyloidosis prevention studies and ANCA vasculitis with end-stage renal disease. Their clinical trials program emphasizes innovative drug combinations, biomarker discovery, and precision medicine approaches, including first-in-human studies and phase III comparative effectiveness trials. The institution is particularly active in exploring novel immunotherapies and targeted agents for both common and rare malignancies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 20 therapeutic areas and 15 of 213 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 200 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 39 by active trials.
lock +38 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC8trials
lock +26 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hopital Henri Mondor - 1 rue Gustave Eiffel
lock Showing 1 of 124 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A DOSE-BLINDED EXTENSION STUDY TO EVALUATE THE LONG-TERM EFFICACY, SAFETY, AND TOLERABILITY OF UCB0599 IN STUDY PARTICIPANTS WITH PARKINSON’S DISEASE | UCB Biopharma | Phase II | Not Recruiting | Dec 2022 | Mar 2025 |
IMP list
lock Showing 1 of 213 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 10 | Unknown | 2021-02-24 | 2025-06-27 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.